Reference for Chapter 121: Dermatoses Induced by Illicit Drugs

1 Gossop M, Marsden J, Stewart D, et al. Substance use, health and social problems of service users at 54 drug treatment agencies: intake data from the National Treatment Outcome Research Study. Br J Psych 1998;173:146–71. Cross Ref link
2 US Department of Justice. The Economic Impact of Illicit Drug Use on American Society. Washington: US Department of Justice, 2011.
3 Hennings C, Miller J. Illicit drugs: what dermatologists need to know. J Am Acad Dermatol 2013;69:135–42. Cross Ref link Pubmed link
4 European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Annual Report 2011: the State of the Drugs Problem in Europe. Luxembourg: Publications Office of the European Union, 2011.
5 Ben Amar M, Potrin S. Cannabis and psychosis: what is the link? J Psychoactive Drugs 2007:39:131–42. Cross Ref link Pubmed link
6 Peyrot I, Garsaud AM, Saint‐Cyr I, Quitman O, Sanchez B, Quist D. Cannabis arteritis: a new case report and a review of literature. J Eur Acad Dermatol Venereol 2007;3:388–91. Cross Ref link
7 Noel B, Ruf I, Panizzon G. Cannabis arteritis. J Am Acad Dermatol 2008;58(Suppl.):S65. Cross Ref link Pubmed link
8 Kutzman TL, Otsuka KN, Wahl RA. Inhalant abuse by adolescents. J Adolesc Health 2001;28:170–80. Cross Ref link Pubmed link
9 Williams JF, Storck MD. Inhalant abuse. Paediatrics 2007;119:1009–17. Cross Ref link
10 Kurniali PC, Henry L. Inhalant abuse of computer cleaner manifested as angioedema. J Emer Med 2012;30:265.e3–5.
11 Kurbat RS, Pollack CV. Facial injury and airway threat from inhalant abuse. J Emerg Med 1998;16:167–9. Cross Ref link Pubmed link
12 Ben‐Abraham R, Szold O, Rudick V, Weinbroum AA. ‘ Ecstasy’ intoxication: life‐threatening manifestations and resuscitative measures in the intensive care setting. Eur J Emerg Med 2003;10:309–13. Cross Ref link Pubmed link
13 Mechan AO, Esteban B, O'Shea E, et al. The pharmacology of the acute hyperthermic response that follows administration of 3,4‐methylenedioxymethamphetamine (MDMA ‘ecstasy’) to rats. Br J Pharmacol 2002;135:170–80. Cross Ref link Pubmed link
14 Wollina U, Kammler HJ, Hesselbarth N, et al. Ecstasy pimples – a new facial dermatosis. Dermatology 1998;197:171–3. Cross Ref link Pubmed link
15 Grant KM, LeVan TD, Wells SM, et al. Methamphetamine‐associated psychosis. J Neuroimmune Pharmacol 2012:7:113–39. Cross Ref link Pubmed link
16 Rusywiak DE. Neurologic manifestations of chronic amphetamine abuse. Neurol Clin 2011;29:641–55. Cross Ref link Pubmed link
17 Hamamoto DT, Rhodus NL. Methamphetamine abuse and dentistry. Oral Dis 2009;15:27–37. Cross Ref link Pubmed link
18 Liu SW, Lien MH, Fenske NA. The effects of alcohol and drug abuse on the skin. Clin Dermatol 2010;28:391–9. Cross Ref link Pubmed link
19 Trimarchi M, Gregorini G, Facchetti F, et al. Cocaine‐induced midline destructive lesions: clinical, radiologic, histopathologic and serologic features. Medicine (Baltimore) 2001;80:391–404. Cross Ref link Pubmed link
20 Vergara‐Moragues E, Araos Gomez P, Gonzalez‐Saiz F, Rodriguez‐Fonseca F. Cocaine‐induced psychotic symptoms in the clinical setting. Psychiatry Res 2014:217:115–20. Cross Ref link
21 Brewer JD, Meves A, Bostwich JM, Pittelkow MR. Cocaine abuse: dermatologic manifestations and therapeutic approaches. J Am Acad Dermatol 2008;59:483–7. Cross Ref link Pubmed link
22 Jimenez‐Gallo D, Albarran‐Planelles C, Linares‐Barrios M, et al. Pyoderma gangrenosum and Wegener granulomatosis‐like syndrome induced by cocaine. Clin Exp Dermatol 2013;38:878–82. Cross Ref link Pubmed link
23 Strazzula L, Brown KK, Brieva JC, et al. Levamisole toxicity mimicking autoimmune disease. J Am Acad Dermatol 2013;69:954–9. Cross Ref link Pubmed link
24 Farmer RW, Malhotra PS, Mays MP, et al. Necrotising peripheral vasculitis/vasculopathy following the use of cocaine laced with levamisole. J Burn Care Res 2012;33:e6–e11. Cross Ref link Pubmed link
25 Jacob RS, Silva CY, Powers JG, et al. Levamisole‐induced vasculopathy: a report of 2 cases and a novel histopathologic finding. Am J Dermatopathol 2012;34:208–13. Cross Ref link Pubmed link
26 McGrath MM, Isakova T, Rennke HG, et al. Contaminated cocaine and anti‐neutrophil cytoplasmic antibody‐associated disease. Clin J Am Soc Nephrol 2011;6:2799–805. Cross Ref link Pubmed link
27 Gahr M, Freudenmann RW, Hiemke C, et al. Desomorphine goes ‘crocodile’. J Addict Dis 2012:31:407–12. Cross Ref link Pubmed link
28 Haemmig RB, Tschacher W. Effects of high‐dose heroin versus morphine in intravenous drug users: a randomised double‐blind crossover study. J Psychoactive Drugs 2001:33:105–10. Cross Ref link Pubmed link
29 Weidman AI, Fellner MJ. Cutaneous manifestations of heroin and other addictive drugs. NY State J Med 1971;71:2643–6.
30 Del Giudice P. Cutaneous complications of intravenous drug abuse. Br J Dermatol 2004;150:1–10. Cross Ref link Pubmed link
31 Darke S, Ross J, Kaye S. Physical injecting sites among injecting drug users in Sydney, Australia. Drug Alcohol Depend 2001;62:77–82. Cross Ref link Pubmed link
32 Rosen VJ. Cutaneous manifestations of drug abuse by parenteral injections. Am J Dermatopathol 1985:7:79–83. Cross Ref link Pubmed link
33 Palestine RF, Millns JL, Spigel JL, Schroeter AL. Skin manifestations of pentazocine abuse. J Am Acad Dermatol 1980;2:47–55. Cross Ref link Pubmed link
34 Farrant P, Creamer D, Fuller C. Extensive cutaneous fibrosis and ulceration caused by methadone injection. Clin Exp Dermatol 2005;30:87–8. Cross Ref link Pubmed link
35 Coughlin PA, Mavor AI. Arterial consequences of recreational drug use. Eur J Vasc Endovasc Surg 2006:32:389–96. Cross Ref link Pubmed link
36 Simonnet N, Marcantoni N Simonnet L, et al. Puffy hand in long‐term intravenous drug users. J Mal Vasc 2004:29:201–4. Cross Ref link Pubmed link
37 Marks M, Pollock S, Morris‐Jones S, et al. Needles and the damage done: reasons for admission and financial costs associated with injecting drug use in a Central London teaching hospital. J Infect 2013:66:95–102. Cross Ref link Pubmed link
38 Vishov D, Sullivan M, Astemborski J, Nelson KE. Bacterial infections and skin cleaning prior to infection among intravenous drug users. Public Health Rep 1992;107:595–8. Pubmed link
39 Binswanger IA, Kral AH, Bultenthal RN, et al. High prevalence of abscesses and cellulitis among community‐recruited injection drug users in San Francisco. Clin Infect Dis 2000:30:579–81. Cross Ref link Pubmed link
40 Gordon RJ, Lowy FD. Bacterial infections in drug users. New Engl J Med 2005;353:1945–54. Cross Ref link Pubmed link
41 Murphy EL, DeVita D, Liu H, et al. Risk factors for skin and soft tissue abscesses among drug users: a case control study. Clin Infect Dis 2001;33:35–40. Cross Ref link Pubmed link
42 Brown PD, Ebright JR. Skin and soft tissue infections in injection drug users. Curr Infect Dis Rep 2002:4:415–19. Cross Ref link Pubmed link
43 Yuan J, Inami G, Mohle‐Boetani J, Vagia DJ. Recurrent wound botulism among injection users in California. Clin Infect Dis 2011:52:862–6. Cross Ref link Pubmed link
44 Hope VD, Palmateer N, Wiessing L et al. A decade of spore‐forming bacterial infections among European injecting users: pronounced regional variation. Am J Public Health 2012: 102:122–5. Cross Ref link Pubmed link
45 Brett MM, Hood J, Brazier JS, et al. Soft tissue infections caused by spore‐forming bacteria in injecting drug users in the United Kingdom. Epidemiol Infect 2005:133:575–82. Cross Ref link Pubmed link
46 Dunbar NM, Harruff RC. Necrotising fasciitis: manifestations, microbiology and connection with black tar heroin. J Forensic Sci 2007;52:920–3. Cross Ref link Pubmed link
47 Collingnon PJ, Sorrell TC. Disseminated candidiasis: evidence of a distinctive syndrome in heroin abusers. BMJ 1983;287:861–2. Cross Ref link Pubmed link
48 Ditzen A, Ehricht R, Monecke S. Disseminated cutaneous and pulmonary abscesses in an injecting drug user caused by a Panton–Valentine leucocidin‐positive, methicillin‐susceptible Staph. aureus strain. Eur J Clin Microbiol Infect Dis 2008:27:1013–15. Cross Ref link Pubmed link

Log in to Rooks online